News & Analysis as of

Canadian Patent Office Canada

Smart & Biggar

Three ways to save on official fees at the Canadian Patent Office before January 1, 2024

Smart & Biggar on

Earlier this year, the Canadian Patent Office announced that it will increase its official fees on January 1, 2024, in some cases by as much as 36%.  As a cost-saving measure, applicants and patentees may wish to pay...more

Smart & Biggar

Canadian Patent law 2022: A Year in Review

Smart & Biggar on

2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for excessive pricing of patented medicines; and a range of court decisions...more

Mintz - Intellectual Property Viewpoints

Obviousness-Type Double Patenting and Divisional Applications in Canada

Obviousness-type double patenting (“OTDP”) arises when two or more patents or applications include claims that, while not being identical, are not patentably distinct from each other. In the U.S., OTDP rejections can be...more

Smart & Biggar

Allowance of Choueifaty patent application provides insight into CIPO's future approach to patentable subject matter

Smart & Biggar on

In an apparent conclusion to the patent at the heart of the Federal Court of Canada’s decision in Yves Choueifaty v Attorney General of Canada, 2020 FC 837 [Choueifaty], Canadian patent application no. 2635393 (CA ‘393) was...more

Smart & Biggar

Canadian Patent Law 2020: A Year in Review

Smart & Biggar on

2020 was an unusual year by all accounts. In this article we take a look back at developments in Canadian patent law in the past year, including the Government of Canada’s and the Canadian Patent Office’s response to...more

Smart & Biggar

Office Actions: Options to consider when you need an extension of time to respond to the Patent Office

Smart & Biggar on

The extensive amendments to the Patent Act and Patent Rules that came into force on October 30, 2019 have complicated the practice for responding to an Office Action (i.e. an “Examiner’s Report”) issued by the Canadian Patent...more

Smart & Biggar

The final Thanksgiving… without a Canadian patent application filing date

Smart & Biggar on

As Canadians begin to prepare for the first public holiday of the fall season, thoughts of turkey (or tofurkey), stuffing and loved ones gathered around the dinner table may serve to distract from the fact that the Canadian...more

Smart & Biggar

Rx IP Update - July 2018

Smart & Biggar on

IN THIS ISSUE: - Shire’s VYVANSE patent valid, prohibition order issued - First judicial consideration of Vanessa’s Law: Health Canada must disclose requested clinical trial data - PMPRB News - Patented Medicine...more

Smart & Biggar

Understanding the similarities and differences between priority claims in Canada and the U.S.

Smart & Biggar on

A valid priority claim can allow a patent application to benefit from the filing date of an earlier patent application so as to exclude certain prior art from consideration. The recent decision of the U.S. Federal Circuit in...more

Smart & Biggar

Bill C-30 to implement CETA tabled in Canadian Parliament: implications for pharmaceuticals

Smart & Biggar on

On October 31, 2016, the day following the signing of CETA, the Canadian Minister of International Trade, the Honourable Chrystia Freeland, tabled Bill C-30, An Act to implement the Comprehensive Economic and Trade Agreement...more

10 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide